Overview of Insider Trading Activity#

On Tuesday, several notable insider trading activities were reported for US-listed stocks, highlighting significant purchases by company directors.

Major Buys at PROCEPT BioRobotics#

PROCEPT BioRobotics Corp experienced the largest insider purchase of the day. Director Rohit Desai bought shares worth over $10.4 million in multiple transactions between March 5 and March 9, 2026. The shares were acquired at prices ranging from approximately $23.33 to $26.41. Notably, on March 5, Desai purchased 142,498 shares and 24,748 shares, followed by 106,554 shares and 53,763 shares on March 6, and 43,581 shares, 53,818 shares, and 1,300 shares on March 9. Despite the stock trading at $25.26, down 57% over the past year, some analyses suggest the company may be undervalued.

Eastern Co's Insider Activity#

Eastern Co attracted interest from Barington Companies Equity Partners L.P., which acquired 7,409 common shares in two transactions on March 6 and March 9, 2026, at prices between $18.29 and $18.74, totaling $136,553. Following these transactions, Barington Companies holds 642,342 indirectly owned shares. Additionally, director James A. Mitarotonda reported direct ownership of 42,794 shares. Eastern Co is currently trading at $19.21, close to its 52-week low of $17.61, and is noted for its 56 consecutive years of dividend payments, offering a 2.31% dividend yield.

Confidence in Grocery Outlet#

Grocery Outlet Holding Corp received a boost from director John E. Bachman, who purchased shares valued at $103,314 on March 6, 2026. The acquisition included 16,000 shares bought in two parts: 4,558 shares at $6.45 each and 11,442 shares at $6.46 each, indicating confidence in the company’s prospects.

Mesa Laboratories' Recent Purchase#

Mesa Laboratories Inc saw director Mark Christopher Capone acquire 1,301 shares on March 10, 2026, for a total of $99,331 at a price of $76.35 per share. This purchase comes after the stock fell nearly 20% over the past week, currently trading at $73.47. Some analyses suggest that Mesa Labs may also be undervalued, with a solid financial health score of 2.71 and a notable history of dividend payments.